Bear Stearns maintains MedImmune at peer perform

MedImmune Inc. was maintained by Bear Stearns analyst Mark Schoenebaum at a peer perform rating after the company revealed the CAIV-T phase 3 trial is on track with full data to be presented at a medical meeting in May. The company also plans in the second quarter of 2006 to apply for a label expansion to include children under 2 despite the wheezing signal seen in phase 3. A European Union partnership on CAIV-T is likely in the next 12 to 18 months, Bear Stearns said. Shares of the Gaithersburg, Md., biotechnology company were down 17 cents, or 0.47%, at $35.67 on volume of 1,397,835 shares versus the three-month running average of 2,760,790 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.